Health services research (text messages, smart pill bottle) for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PAAcute Myeloid LeukemiaBehavioral, Psychological or Informational Intervention - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a mobile intervention to help AML patients take their oral anti-cancer meds correctly. It may help doctors design better educational material to improve adherence.

Eligible Conditions
  • Acute Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
APVO436
1
Nerofe
1
DVX201

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: At baseline, 1, and 2 months

At 2 months
Leukemia, Myelocytic, Acute
Antibiotics, Antineoplastic
Month 2
Complete remission (CR)
Complete Blood Count
Morphologic leukemia-free state (MLFS)
Partial remissions (PR)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
APVO436
1
Nerofe
1
DVX201

Trial Design

1 Treatment Group

Health services research (text messages, smart pill bottle)
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: Health services research (text messages, smart pill bottle) · No Placebo Group · N/A

Health services research (text messages, smart pill bottle)Experimental Group · 4 Interventions: Behavioral, Psychological or Informational Intervention, Survey Administration, Quality-of-Life Assessment, Text Message-Based Navigation Intervention · Intervention Types: Other, Other, Other, Other

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at baseline, 1, and 2 months

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor
409 Previous Clinical Trials
136,045 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

What purposes does this clinical trial seek to fulfill?

"The primary endpoint examined in this clinical trial, to be evaluated at 2 months, is the response rate of patients with acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) based on their MD Anderson Symptom Inventory score. Secondary metrics include complete remission (CR), partial remissions (PR), and morphologic leukemia-free state (MLFS). All outcomes will be analyzed using univariable logistic regression models that focus on a predictor of daily OAM medication adherence." - Anonymous Online Contributor

Unverified Answer

What is the current number of participants in this trial?

"Affirmative. Clinicaltrials.gov displays that this clinical trial, initially posted on August 15th 2022 is currently recruiting patients. 30 individuals are needed between two different medical centres for the study's completion." - Anonymous Online Contributor

Unverified Answer

Are participants currently being enrolled in this clinical experiment?

"As corroborated by clinicaltrials.gov, this study is still recruiting patients as of October 25th 2022. It was initially made available to the public on August 15th 2022." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top